Ultrasound vendor ATL reported lastweek that it is not expecting any improvement in third-quarterrevenues due to ongoing difficult market conditions in the U.S.and Europe. According to preliminary internal estimates conductedby the Bothell, WA-based
Ultrasound vendor ATL reported lastweek that it is not expecting any improvement in third-quarterrevenues due to ongoing difficult market conditions in the U.S.and Europe. According to preliminary internal estimates conductedby the Bothell, WA-based company, third-quarter revenues willprobably be similar to, but will not exceed, those of the secondquarter of this year. ATL reported second-quarter revenue of $84.8million, down 5% compared to the same period a year ago (SCAN8/10/94).
ATL is pinning hopes for a recovery in part on Apogee 800,a mid-range scanner acquired through the vendor's merger withInterspec. ATL is in the midst of a worldwide roll-out of theproduct.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.